It's not unusual for medical device firms to buy overseas distributors who have been successful in selling their products. But in the case of St. Jude and Getz Brothers, the deal raises questions about both companies' future relationships with past partners.
It's not unusual for device companies to acquire their overseas distributors, particularly midway in their evolution to maturity and market leadership as they transform a distribution relationship into a direct selling effort. But for mature, well-established companies, with diverse product lines, such a strategy can sometimes be less than straightforward.
On its face, St. Jude Medical Inc. 's announced acquisition of its leading Japanese distributor, Getz Bros. & Co....
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
